GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solventum Corp (MEX:SOLV) » Definitions » EV-to-EBITDA

Solventum (MEX:SOLV) EV-to-EBITDA : 15.20 (As of Jun. 01, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Solventum EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Solventum's enterprise value is MXN387,076 Mil. Solventum's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was MXN25,473 Mil. Therefore, Solventum's EV-to-EBITDA for today is 15.20.

The historical rank and industry rank for Solventum's EV-to-EBITDA or its related term are showing as below:

MEX:SOLV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.3   Med: 10.72   Max: 15.75
Current: 15.51

During the past 5 years, the highest EV-to-EBITDA of Solventum was 15.75. The lowest was 5.30. And the median was 10.72.

MEX:SOLV's EV-to-EBITDA is ranked better than
50.6% of 496 companies
in the Medical Devices & Instruments industry
Industry Median: 15.76 vs MEX:SOLV: 15.51

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-01), Solventum's stock price is MXN1700.00. Solventum's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was MXN42.214. Therefore, Solventum's PE Ratio (TTM) for today is 40.27.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Solventum EV-to-EBITDA Historical Data

The historical data trend for Solventum's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solventum EV-to-EBITDA Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
- - - - 12.22

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.67 8.17 10.85 12.22 15.91

Competitive Comparison of Solventum's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Solventum's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solventum's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Solventum's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Solventum's EV-to-EBITDA falls into.


;
;

Solventum EV-to-EBITDA Calculation

Solventum's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=387075.867/25472.958
=15.20

Solventum's current Enterprise Value is MXN387,076 Mil.
Solventum's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN25,473 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solventum  (MEX:SOLV) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Solventum's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1700.00/42.214
=40.27

Solventum's share price for today is MXN1700.00.
Solventum's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN42.214.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Solventum EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Solventum's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Solventum Business Description

Traded in Other Exchanges
Address
2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.